Levetiracetam (LEV) is a medication that has been used to treat a variety of neurological conditions, including epilepsy, bipolar disorder, and anxiety. It is a relatively new drug, first approved by the US Food and Drug Administration (FDA) in 1999. While LEV has been found to be effective in treating these conditions, it has also been associated with a number of side effects. This article will explore the unintended consequences of LEV, including potential side effects, drug interactions, and long-term health risks.
Levetiracetam (LEV) is an anticonvulsant medication that is used to treat epilepsy, bipolar disorder, and anxiety. It is a relatively new drug, first approved by the FDA in 1999. LEV works by stabilizing electrical activity in the brain, which helps to reduce seizures and other symptoms associated with these conditions. It is available in tablet, solution, and suspension forms, and is typically taken twice a day.
Like all medications, LEV can cause side effects. The most common side effects of LEV include drowsiness, dizziness, headache, nausea, and vomiting. It can also cause blurred vision, dry mouth, and loss of appetite. These side effects are usually mild and may go away as your body adjusts to the medication. More serious side effects of LEV include difficulty breathing, swelling of the face, throat, or tongue, rash or hives, and seizures.
LEV can interact with other medications, so it is important to tell your doctor about any other medications you are taking. For example, LEV can interact with anticoagulants (blood thinners), such as warfarin, and can increase the risk of bleeding. It can also interact with other anticonvulsants, such as phenytoin, and can increase the risk of seizures. It is also important to tell your doctor if you are taking any herbal supplements, as they can interact with LEV and cause side effects. For example, ginkgo biloba can increase the risk of bleeding, and St. John’s wort can increase the risk of seizures.
There is limited research on the long-term effects of LEV, but some studies suggest that it may increase the risk of certain health conditions. For example, one study found that long-term use of LEV may increase the risk of bone fractures. Another study found that long-term use of LEV may increase the risk of depression and suicidal thoughts. It is important to speak with your doctor about any potential long-term risks of LEV before taking it.
Levetiracetam (LEV) is a medication that is used to treat a variety of neurological conditions, including epilepsy, bipolar disorder, and anxiety. While it can be effective in treating these conditions, it can also cause side effects and interact with other medications. It is also important to be aware of the potential long-term health risks associated with LEV, as some studies suggest that it may increase the risk of certain health conditions. It is important to talk to your doctor about any potential risks before taking LEV.
1.
More Positive Survival Data in Lung Cancer With Perioperative Therapy
2.
Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy
3.
Study finds 10% of pediatric blood cancers may stem from medical imaging radiation
4.
For the creation of cutting-edge targeted radionuclide therapies in oncology, Bayer and Bicycle Therapeutics work together.
5.
Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.
1.
Case Study: Artificial Intelligence in Early Cancer Detection
2.
Understanding Acute Intermittent Porphyria: Symptoms, Diagnosis and Treatment
3.
What is Mullerian and How Does it Affect Your Health
4.
AI in Cancer Care: Transforming Research & Treatment with Deep Learning Technologies
5.
Is p53 the Missing Puzzle Piece? Exploring Its Polymorphisms in Cervical Cancer Risk
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Should We Use DARA Up Front As First-Line Therapy in MM?
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation